Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is HealthCare Global Enterprises EV-to-EBITDA?
HealthCare Global EnterprisesNSE:HCG +4.43%79 EV-to-EBITDA is 26.49 as of Aug. 20, 2026, which is 42% above its 10-year median of 18.60. GuruFocus rates NSE:HCG with a GF Score™ of 79/100 and a GF Value™ of ₹603.76 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 513 Healthcare Providers & Services companies, HealthCare Global Enterprises ranks worse than 83.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HealthCare Global Enterprises's enterprise value is ₹123,881 Mil.
HealthCare Global Enterprises's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹4,677 Mil. Therefore, HealthCare Global Enterprises's EV-to-EBITDA for today is 26.49.
The historical rank and industry rank for HealthCare Global Enterprises's EV-to-EBITDA or its related term are showing as below:
NSE:HCG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.75 Med: 18.6 Max: 87.68
Current: 26.49
During the past 12 years, the highest EV-to-EBITDA of HealthCare Global Enterprises was 87.68. The lowest was 4.75. And the median was 18.60.
NSE:HCG's EV-to-EBITDA is ranked worse than 83.43% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.76
vs NSE:HCG: 26.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
HealthCare Global Enterprises (NSE:HCG) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HealthCare Global Enterprises's PE Ratio (TTM) for today is calculated as:
HealthCare Global Enterprises's share price for today is ₹745.25.
HealthCare Global Enterprises's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.547.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, HealthCare Global Enterprises's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthCare Global Enterprises EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthCare Global Enterprises's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HealthCare Global Enterprises's EV-to-EBITDA falls into.
HealthCare Global Enterprises's current Enterprise Value is ₹123,881 Mil.
HealthCare Global Enterprises's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,677 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthCare Global Enterprises (NSE:HCG) has a EV-to-EBITDA of 26.49 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HealthCare Global Enterprises. This is 42% above median its historical median of 18.60. Over the past decade, HealthCare Global Enterprises' EV-to-EBITDA has ranged from 4.75 to 87.68. According to the industry distribution chart, HealthCare Global Enterprises ranks #428 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 83.4%.
Is HealthCare Global Enterprises' EV-to-EBITDA too high?
HealthCare Global Enterprises' current EV-to-EBITDA of 26.49 is 42% above median its 10-year median of 18.60. Over the past 10 years, this metric has ranged from a low of 4.75 to a high of 87.68. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.76. HealthCare Global Enterprises' value of 26.49 is 146.2% above this industry median. Based on the distribution chart, HealthCare Global Enterprises ranks #428 out of 513 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, HealthCare Global Enterprises has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HealthCare Global Enterprises' EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, HealthCare Global Enterprises ranks #428 out of 513 companies for EV-to-EBITDA. This places HealthCare Global Enterprises in the lower half of its industry. The industry median EV-to-EBITDA is 10.76. HealthCare Global Enterprises' value of 26.49 is 146.2% above this benchmark. Historically, HealthCare Global Enterprises' own EV-to-EBITDA has ranged from 4.75 to 87.68 over the past decade. While the company's 10-year median is 18.60 vs. the industry median of 10.76, HealthCare Global Enterprises has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.76, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HealthCare Global Enterprises's current EV-to-EBITDA of 26.49 is 146.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on HealthCare Global Enterprises. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HealthCare Global Enterprises's current EV-to-EBITDA is 26.49, which is 42% above median its own 10-year median of 18.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthCare Global Enterprises stock overvalued right now?
Based on GuruFocus' analysis, HealthCare Global Enterprises (NSE:HCG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹603.76, compared to a current price of ₹745.25 — trading 23.4% above its estimated fair value. The current EV-to-EBITDA is 26.49, which is 42% above median its 10-year median of 18.60 and 146.2% above the Healthcare Providers & Services industry median of 10.76. HealthCare Global Enterprises' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For HealthCare Global Enterprises (NSE:HCG), the current EV-to-EBITDA is 26.49 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthCare Global Enterprises (NSE:HCG) Overvalued in 2026?
Based on GuruFocus' analysis, HealthCare Global Enterprises stock appears to be overvalued.
The current stock price of ₹745.25 is trading 23.4% above its estimated GF Value™ of ₹603.76.
GuruFocus considers HealthCare Global Enterprises to be Modestly Overvalued.
Key valuation signals for NSE:HCG:
EV-to-EBITDA: 26.49 (42% above median its 10-year median of 18.60)
GF Value™: ₹603.76 vs. price of ₹745.25 (23.4% above fair value)
Industry Position: 146.2% above the Healthcare Providers & Services median (#428 of 513)
No single metric tells the full story. See the NSE:HCG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthCare Global Enterprises Ltd operates in oncology, providing comprehensive cancer diagnosis and treatment services including medical oncology, radiation therapy, and surgical oncology. It also offers fertility treatment services under the Milann brand, along with multi-specialty hospital care in key medical disciplines. The company's operations span many metropolitan and non-metro cities across India and extend internationally with cancer care centers in Africa. HCG generates revenue through patient services in oncology, fertility treatments, diagnostics, and multi-specialty hospital care, leveraging technology and a networked business model to deliver patient-centric healthcare.
79GF Score
Get the complete analysis for NSE:HCG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HCG has been successfully added to your 
